Series A recap round brings Domain Therapeutics €2.1mm

Domain Therapeutics SA (develops small molecules that target GPCRs) has raised €2.1mm ($2.8mm) in a Series A recapitalization round from first-time backers Alsace Inter Regio Fonds d'Investissement (AIRFI), Alsace Creation, and individuals, as well as returning shareholders AGF Private Equity, Auriga Partners, Edmond de Rothschild Investment Partners, and Sofinnova Partners. The financing marks at least the fourth time the French biotech has brought in funding, which now amounts to $34.7mm since it was founded in 2001. The company recently changed its name from Faust Pharmaceuticals to reflect its new strategy--broadening GPCR drug discovery beyond neurology to all indications.